Why has the CSL share price lagged the ASX 200 over the past week?

CSL shares have been treading lower of late…

| More on:
A scientist examining test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares have shed 1.48% over the past week
  • Investors seemed to have turned their attention to the rising ASX 300 Metals & Mining sector following a commodity boom in recent times
  • CSL previously advised that the Vifor Pharma acquisition is expected to be delayed by a few months

The CSL Ltd (ASX: CSL) share price has edged 1.48% lower since this time last week.

While the global biotech hasn't released any market sensitive news in that time, investors have been offloading the company's shares.

CSL shares closed a further 0.73% down on Monday at $273.15 each.

What's weighing down CSL shares lately?

A couple of factors are playing against CSL shares for the moment as the COVID-19 pandemic begins to subside.

First and foremost, the S&P/ASX 200 Health Care index (ASX: XHJ) has reversed its gains over the past week, down 0.3%. The index closed another 0.16% lower today.

Investors appear to have focused their efforts on better performing ASX sectors such as the S&P/ASX 300 Metals & Mining (ASX: XMM) index. This consists of the top 300 ASX companies that are involved with gold, steel, and precious metals.

For context, the Metals & Mining sector has soared 5.96% from this time last Monday.

And it's no surprise that commodity prices have skyrocketed, given the war in Ukraine and inflationary movements.

Market psychology can be a powerful force when crowd behaviour chases market rallies or selloffs during downturns.

Another factor that has led CSL shares to fall is the delay to complete the acquisition of Vifor Pharma.

Originally, the deal was due to be wrapped up by June 2022. However, receiving regulatory approvals is taking a little longer.

As such, CSL now expects the takeover to be finalised within the next few months.

CSL share price snapshot

Uncharacteristically, it has been a turbulent year for CSL shareholders, recording a loss of 4% over the last 12 months.

Year to date has not fared any better with the company's shares down 6%.

Based on valuation grounds, CSL commands a market capitalisation of roughly $131.5 billion.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »